Potential Involvement of Fructosylated Human Insulin and Serological Evidence in Subclinical Autoimmune Activity in Type 2 Diabetes Mellitus. | Synapse
March 16, 2026
Potential Involvement of Fructosylated Human Insulin and Serological Evidence in Subclinical Autoimmune Activity in Type 2 Diabetes Mellitus.
Key Points
To explore the role of fructosylated insulin and detect subclinical autoimmune activity in type 2 diabetes mellitus (T2DM).
Screening for anti-fructosylated insulin antibodies in T2DM patients
Assessment of hyperglycemia-associated autoimmune activity
Evaluation of insulin responses under abnormal conditions
Identification of subclinical autoimmune activity linked to abnormal insulin responses
Association between hyperglycemia and presence of antibodies
Enhanced understanding of autoimmune mechanisms in T2DM
Abstract
Screening for anti-fructosylated insulin antibodies may help identify T2DM patients with hyperglycemia-associated, subclinical autoimmune activity linked to abnormal insulin responses. .